TY - JOUR
T1 - Molecular and translational advances in meningiomas
AU - International Consortium on Meningiomas
AU - Suppiah, Suganth
AU - Nassiri, Farshad
AU - Bi, Wenya Linda
AU - Dunn, Ian F.
AU - Hanemann, Clemens Oliver
AU - Horbinski, Craig M.
AU - Hashizume, Rintaro
AU - James, Charles David
AU - Mawrin, Christian
AU - Noushmehr, Houtan
AU - Perry, Arie
AU - Sahm, Felix
AU - Sloan, Andrew
AU - Von Deimling, Andreas
AU - Wen, Patrick Y.
AU - Aldape, Kenneth
AU - Zadeh, Gelareh
AU - Au, Karolyn
AU - Barnhartz-Sloan, Jill
AU - Brastianos, Priscilla K.
AU - Butowski, Nicholas
AU - Carlotti, Carlos
AU - Cusimano, Michael D.
AU - Dimeco, Francesco
AU - Drummond, Katharine
AU - Galanis, Evanthia
AU - Giannini, Caterina
AU - Goldbrunner, Roland
AU - Griffith, Brent
AU - Herold-Mende, Christel
AU - Huang, Raymond Y.
AU - James, David
AU - Jenkinson, Michael D.
AU - Jungk, Christine
AU - Kaufman, Timothy J.
AU - Krischek, Boris
AU - Lachance, Daniel
AU - Lafougère, Christian
AU - Lee, Ian
AU - Liu, Jeff C.
AU - Mamatjan, Yasin
AU - Mansouri, Alireza
AU - McDermott, Michael
AU - Munoz, David
AU - Ng, Ho Keung
AU - Pirouzmand, Farhad
AU - Poisson, Laila M.
AU - Pollo, Bianca
AU - Raleigh, David
AU - Saladino, Andrea
N1 - Publisher Copyright:
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.
PY - 2019/1/14
Y1 - 2019/1/14
N2 - Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treatment options for symptomatic meningiomas are limited to surgical resection where possible and adjuvant radiation therapy for tumors with concerning histopathological features or recurrent disease. At present, alternative adjuvant treatment options are not available in part due to limited historical biological analysis and clinical trial investigation on meningiomas. With advances in molecular and genomic techniques in the last decade, we have witnessed a surge of interest in understanding the genomic and epigenomic landscape of meningiomas. The field is now at the stage to adopt this molecular knowledge to refine meningioma classification and introduce molecular algorithms that can guide prediction and therapeutics for this tumor type. Animal models that recapitulate meningiomas faithfully are in critical need to test new therapeutics to facilitate rapid-cycle translation to clinical trials. Here we review the most up-to-date knowledge of molecular alterations that provide insight into meningioma behavior and are ready for application to clinical trial investigation, and highlight the landscape of available preclinical models in meningiomas.
AB - Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treatment options for symptomatic meningiomas are limited to surgical resection where possible and adjuvant radiation therapy for tumors with concerning histopathological features or recurrent disease. At present, alternative adjuvant treatment options are not available in part due to limited historical biological analysis and clinical trial investigation on meningiomas. With advances in molecular and genomic techniques in the last decade, we have witnessed a surge of interest in understanding the genomic and epigenomic landscape of meningiomas. The field is now at the stage to adopt this molecular knowledge to refine meningioma classification and introduce molecular algorithms that can guide prediction and therapeutics for this tumor type. Animal models that recapitulate meningiomas faithfully are in critical need to test new therapeutics to facilitate rapid-cycle translation to clinical trials. Here we review the most up-to-date knowledge of molecular alterations that provide insight into meningioma behavior and are ready for application to clinical trial investigation, and highlight the landscape of available preclinical models in meningiomas.
UR - http://www.scopus.com/inward/record.url?scp=85060044130&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060044130&partnerID=8YFLogxK
U2 - 10.1093/neuonc/noy178
DO - 10.1093/neuonc/noy178
M3 - Article
C2 - 30649490
AN - SCOPUS:85060044130
SN - 1522-8517
VL - 21
SP - I4-I17
JO - Neuro-oncology
JF - Neuro-oncology
ER -